The interferon-induced transmembrane protein 1 (IFITM1) is a key member of the IFITM family, which is part of the interferon-stimulated genes (ISGs) activated during innate immune responses. Primarily known for its role in restricting viral entry, IFITM1 inhibits infections by enveloped viruses like influenza, dengue, and HIV by altering membrane fluidity and blocking viral fusion. Beyond antiviral defense, IFITM1 is implicated in cell adhesion, signal transduction, and cancer progression, acting as either a tumor suppressor or promoter depending on context.
IFITM1 antibodies are critical tools for detecting and studying this protein’s expression, localization, and function. Typically generated using recombinant proteins or synthetic peptides, these antibodies (polyclonal or monoclonal) are validated for specificity in applications such as Western blotting, immunofluorescence, immunohistochemistry, and flow cytometry. Cross-reactivity with homologous family members (e.g., IFITM2/3) remains a challenge, necessitating careful validation via knockout controls.
Research utilizing IFITM1 antibodies has advanced understanding of viral pathogenesis, cancer biology, and immune regulation. Their role in characterizing IFITM1’s dual functions in health and disease underscores their value in exploring therapeutic strategies or biomarkers for infections and malignancies.